Spectrum Strategic Capital Management LLC Acquires New Holdings in Abbott Laboratories $ABT

Spectrum Strategic Capital Management LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,981 shares of the healthcare product maker’s stock, valued at approximately $1,000,000.

Other institutional investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter valued at approximately $31,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories in the third quarter worth $33,000. Finally, Copia Wealth Management purchased a new position in Abbott Laboratories in the third quarter worth $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Bank of America cut their price target on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. UBS Group cut their price target on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Raymond James Financial cut their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Evercore cut their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $84.49 on Monday. The firm has a market capitalization of $147.16 billion, a PE ratio of 23.67, a price-to-earnings-growth ratio of 1.41 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company’s fifty day moving average price is $99.02 and its 200-day moving average price is $113.25.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. Abbott Laboratories’s payout ratio is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.